Guardant Health 株価情報 (NASDAQ: GH)

Guardant Health (NASDAQ:GH) 株価情報

Guardant Health

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Inc

Gresham Technologies PLC

Grand Havana Inc

Glass House Brands Inc Warrants (15/01/2026)

Glass House Brands Inc

Graham Holdings Co

Galaxy Heroes Coin

Collaborative Investment Series Trust Goose Hollow Hedged Equity ETF

GreenTree Hospitality Group Ltd. American depositary shares, each representing one Class A ordinary share

GreenTree Hospitality Group Ltd

GUANHUA CORPORATION by GuanHua Corporation

GuanHua Corp

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Greystone Housing Impact Investors LP

Gamehost Inc

GREEN AND HILL INDUS INC by Green and Hill Industries, Inc.

Green and Hill Industries Inc

Gores Holdings IX Inc Ordinary Shares - Class A

Gores Holdings IX Inc

Gores Holdings IX Inc Units (1 Ord Class A & 1/3 War)

Gores Holdings IX Inc Warrants (31/01/2027)

Greenhill & Co Inc Com

Guild Holdings Company Class A Common Stock

Guild Holdings Co

Graham Corp

Accredited Solutions Inc

Collaborative Investment Series Trust Goose Hollow Multi-Strategy Income ETF

GHO - United States Dollar

Ghost

GOLD HUNTER RES INC by GOLD HUNTER RES INC

Gold Hunter Resources Inc

GOLDEN HORSE MINERALS LTD by GOLDEN HORSE MINERALS LTD

Golden Horse Minerals Ltd

GH Research PLC

GREENHEART GOLD INC by GREENHEART GOLD INC.

Guardion Health Sciences Inc

GHST World Inc

Aavegotchi - United States Dollar

Goose Hollow Tactical Allocation ETF

G-H-3 INTERNATIONAL INC by G-H-3 International, Inc.

G-H-3 International Inc

GoldHaven Resources Corp Ordinary Shares

GOLDHAVEN RESOURCES CORP by GoldHaven Resources Corp

GoldHaven Resources Corp

GamerCoin

PGIM Global High Yield Fund, Inc

Goldman Sachs Access High Yield Corporate Bond ETF

iShares US & Intl High Yield Corp Bond ETF

GOLD HYDROGEN LIMITED by Gold Hydrogen Limited

Gold Hydrogen Ltd

The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.

News

ARMP

Armata Enters $10M Secured Credit Agreement With Innoviva Strategic Opportunities LLC

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Health Care

Analyst Ratings

General

MYGN

VCYT

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon is no stranger to making bold predictions about the economy. His latest comments suggest storm clouds <a href="https://www.benzinga.com/25/03/44270128/us-recession-probability-escalates-to-35-amid-tariffs-pimco-sounds-alarm">could be forming once again</a>.
What To Know: At the 2025 National Retirement Summit hosted by BlackRock and Semafor on Wednesday, Dimon warned that he sees a weakening of the economy and negative sentiment, according to an X <a href="https://x.com/SpencerHakimian/status/1899879996304273725">post</a> from Tolou Capital Management founder Spencer Hakimian. The post also indicates that Dimon believes tariffs are causing uncertainty.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x2A;JP MORGAN&#39;S CEO DIMON: SEEING WEAKENING IN ECONOMY, NEGATIVE SENTIMENT &#x2A;DIMON SAYS TARIFFS ARE CAUSING UNCERTAINTY Most important private sector human on earth telling it to you straight up.
&mdash; Spencer Hakimian (@SpencerHakimian) <a href="https://twitter.com/SpencerHakimian/status/1899879996304273725?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Semafor Principals editor Morgan Chalfant also reported similar details from the event in a separate X <a href="https://x.com/mchalfant16/status/1899878158389719290">post</a>. Chalfant noted that although Dimon said <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">consumer sentiment is weakening</a>, the JPMorgan chief indicated that he doesn&#8217;t believe the average American &#8220;changes what they&#8217;re going to do&#8221; because of tariffs.
Dimon isn&#8217;t always spot-on with his predictions. In late 2022, he warned that an <a href="http://www.benzinga.com/news/22/10/29208975/jamie-dimon-warns-of-u-s-recession-in-6-9-months-says-jp-morgan-preparing-for-economic-hurricane" target="_blank" rel="noreferrer noopener">economic &#8220;hurricane&#8221;</a> was coming in mid-2023.
Dimon later walked back those comments after data showed otherwise.
&#8220;I shouldn't ever use the word hurricane, but &#8230; there were storm clouds,&#8221; Dimon <a href="https://www.benzinga.com/news/23/01/30358567/i-shouldnt-ever-use-the-word-hurricane-jamie-dimon-says-storm-clouds-remain-but-the-consumer-is-roll">said</a> in a 2023 interview.
It&#8217;s not clear if Dimon sees &#8220;storm clouds&#8221; over the economy this time around, but he at least appears to be taking a cautious stance. 
Price Action: <a href="http://benzinga.com/quote/jpm">JPMorgan shares</a> were up 0.61% at $230.50 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44280431/cpi-reactions">Inflation Moves In The &#8216;Right Direction&#8217; But Forecast Is Hazy, Economist Says</a></li>
</ul>
Photo: Shutterstock.

Events

Jamie Dimon Warns Of Economic Weakening, Negative Consumer Sentiment

<h3>Gainers</h3>
<ul>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) stock moved upwards by 9.1% to $2.15 during Wednesday's after-market session. The market value of their outstanding shares is at $109.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) shares increased by 6.47% to $1.81. The market value of their outstanding shares is at $581.7 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) stock increased by 5.51% to $3.06. The company's market cap stands at $402.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares rose 5.0% to $0.43. The company's market cap stands at $7.3 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares increased by 4.99% to $0.58. The company's market cap stands at $5.7 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) stock increased by 4.82% to $0.5. The company's market cap stands at $35.3 million. The company's, Q4 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) stock declined by 14.0% to $0.03 during Wednesday's after-market session. The company's market cap stands at $16.5 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock decreased by 5.9% to $0.27. The market value of their outstanding shares is at $2.0 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) stock fell 5.34% to $0.53. The company's market cap stands at $7.2 million. </li>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) stock declined by 5.2% to $1.46. The market value of their outstanding shares is at $4.1 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares fell 4.47% to $1.93. The company's market cap stands at $43.7 million. </li>
<li>Able View Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) stock declined by 4.35% to $1.1. The market value of their outstanding shares is at $54.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ABLV

ASST

BHAT

CDLX

CMLS

MITQ

SEAT

STBX

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock increased by 17.4% to $2.46 during Wednesday's after-market session. The market value of their outstanding shares is at $104.0 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock moved upwards by 16.23% to $2.65. The market value of their outstanding shares is at $2.7 million. As per the press release, Q4 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock increased by 12.64% to $0.8. The market value of their outstanding shares is at $18.4 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) shares moved upwards by 12.41% to $1.46. The company's market cap stands at $12.5 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 8.99% to $0.29. The company's market cap stands at $1.8 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock rose 8.19% to $0.75. The company's market cap stands at $128.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock decreased by 52.5% to $0.05 during Wednesday's after-market session. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares declined by 39.27% to $0.03. The company's market cap stands at $2.7 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 18.86% to $0.04. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares fell 9.98% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock declined by 9.76% to $3.7. The company's market cap stands at $115.1 million. As per the press release, Q4 earnings came out today. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.03% to $0.25. The company's market cap stands at $4.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

BSGM

BTMD

CPHI

CUTR

HEPA

HURA

MCRB

SCNX

SNES

SYRS

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock moved upwards by 30.4% to $0.71 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) stock moved upwards by 13.8% to $7.09. The company's market cap stands at $133.9 million. The company's, Q4 earnings came out today. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares moved upwards by 6.22% to $0.51. The market value of their outstanding shares is at $16.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares increased by 5.92% to $0.18. The market value of their outstanding shares is at $23.9 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares increased by 5.45% to $2.9. The company's market cap stands at $7.2 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares moved upwards by 5.28% to $1.59. The market value of their outstanding shares is at $223.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) stock fell 11.3% to $15.83 during Wednesday's after-market session. The market value of their outstanding shares is at $120.2 million. The company's, Q4 earnings came out today. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 9.93% to $0.29. </li>
<li>CDT Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) stock declined by 9.1% to $1.3. The company's market cap stands at $13.9 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock fell 7.77% to $0.57. The market value of their outstanding shares is at $17.0 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock fell 6.98% to $1.6. The company's market cap stands at $89.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares fell 4.78% to $0.47. The company's market cap stands at $11.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CAPT

CDTG

HTCO

POLA

PSIG

RAIL

RCMT

SGBX

VSTE

12 Industrials Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares rose 11.5% to $23.06 during Wednesday's after-market session. The market value of their outstanding shares is at $99.8 billion. </li>
<li>Next Technology Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) shares rose 8.79% to $0.37. The market value of their outstanding shares is at $2.5 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock rose 7.14% to $1.35. The company's market cap stands at $49.5 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) shares moved upwards by 6.66% to $1.44. The market value of their outstanding shares is at $120.3 million. </li>
<li>Valens Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLN#NYSE">VLN</a>) stock rose 6.63% to $2.25. The company's market cap stands at $237.8 million. </li>
<li>CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) shares moved upwards by 6.22% to $7.0. The company's market cap stands at $942.8 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) stock fell 16.1% to $16.2 during Wednesday's after-market session. The market value of their outstanding shares is at $5.2 billion. The company's, Q4 earnings came out today. </li>
<li>Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) stock fell 15.51% to $1.8. The company's market cap stands at $52.4 million. As per the press release, Q2 earnings came out today. </li>
<li>UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) stock declined by 15.14% to $10.04. The market value of their outstanding shares is at $5.5 billion. As per the press release, Q4 earnings came out today. </li>
<li>A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) shares declined by 10.54% to $17.49. The market value of their outstanding shares is at $1.2 billion. </li>
<li>NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) shares decreased by 10.42% to $9.2. The market value of their outstanding shares is at $1.2 billion. As per the news, the Q4 earnings report came out today. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) stock decreased by 6.98% to $3.3. The company's market cap stands at $31.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATEN

CINT

CMTL

INTC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTX

PATH

SatixFy Communications Ltd. Ordinary Share

SATX

TZUP

12 Information Technology Stocks Moving In Wednesday's After-Market Session

MTAL

MAC Copper Amends Debt And Further Simplifies Balance Sheet Through Early Repayment Of Sprott Mezzanine Facility

Groupon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) shares are trading higher Wednesday after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/25/03/44263961/groupon-stock-moves-higher-after-q4-earnings-company-says-momentum-has-carried-into-2025">fourth-quarter results. </a>
What To Know: The company reported revenue totaling $130.38 million, surpassing the $127.74 million estimate. Despite a 4% year-over-year decline in revenue, the results were bolstered by a sequential rebound in unit sales and cash flow generation.
The company also reported a fourth-quarter loss of $1.20 per share, worse than the estimated loss of four cents per share, but it noted significant improvements in other key metrics. Gross billings were down 1% year-over-year, but Groupon ended the quarter with $228.8 million in cash and cash equivalents.
CEO Dusan Senkypl emphasized the company's successful transformation strategy, noting North America Local experienced growth in the quarter, positioning Groupon well for continued momentum into 2025. The company's focus on enhancing customer retention, expanding in key markets and improving merchant success is expected to drive further growth, with guidance for first-quarter revenue of $114 million to $117 million.
The company's shift to a mobile-first platform and focus on high-impact categories are expected to support its performance moving forward.
GRPN Price Action: Groupon shares were up 43.09% at $13.98 at market close Wednesday, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="528" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-1024x528.png" alt="" class="wp-image-821523" style="width:397px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-1024x528.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/12142219/Screenshot-2025-03-12-at-14.21.41.png 1534w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44283118/tesla-loses-ground-in-us-ev-market-while-rivals-accelerate-ahead-in-january-report">Tesla Loses Ground in US EV Market While Rivals Accelerate Ahead in January: Report</a></li>
</ul>
Photo: Shutterstock

Earnings

GRPN

Groupon Shares Are Up Today: What's Going On?

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) released its fourth-quarter results after Wednesday's closing bell. Here's a look at the key figures<a href="https://www.benzinga.com/pressreleases/25/03/b44288526/uipath-acquires-peak-to-launch-vertically-specialized-agents-within-its-agentic-automation-platfor"> from the report.&nbsp;&nbsp;</a>
The Details: UiPath reported quarterly earnings of nine cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue of $424 million missed the analyst consensus estimate of $425.36 million and is an increase over revenue of $405.25 million from the same period last year.
Read More: <a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day">Trump Media &amp; Technology Stock Drops 50% Since Inauguration Day</a>&nbsp;
For the fourth quarter, UiPath reported: 
<ul>
<li>ARR of $1.666 billion as of Jan. 31, 2025, increased 14 percent year-over-year.</li>
<li>Net new ARR&nbsp;of $60 million.</li>
<li>Dollar based net retention rate&nbsp;of 110%.</li>
<li>Non-GAAP gross margin&nbsp;was 87%. </li>
</ul>
&#8220;Fiscal 2025 was our most innovative year in recent history, introducing a wealth of new AI capabilities, and redefining the future of automation through our groundbreaking new products: Autopilot, Agent Builder, Agentic Orchestration, and Agentic Testing,&#8221; said Daniel Dines, UiPath CEO.
The company also announced the acquisition of Peak, an AI-native company, but did not disclose the specific terms of the deal. 
&#8220;With the acquisition of Peak, we are accelerating our mission to strengthen our vertical AI solutions strategy,&#8221; said Dines. 
Outlook:&nbsp;UiPath sees first-quarter revenue in a range of $330 million to $335 million, versus the $368.08 million estimate. 
PATH Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, UiPath shares are down 14.37% after hours at $10.13 Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

UiPath Shares Plunge After Q4 Revenues Miss, Weak Q1 Guidance

When President Trump announced a 50% tariff on Canadian aluminum and steel imports, it created a cloud of fear and <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">uncertainty in the markets</a>. 
Stocks dropped as the 25% previously announced tariffs set to be implemented on Wednesday were anticipated to be doubled.
Trump later hinted at reconsideration after Ontario's premier suspended a surcharge on electricity exports. While domestic producers may benefit, higher costs could dent the profits of industries that rely heavily on these materials.
Also Read: <a href="https://www.benzinga.com/news/25/03/44253100/trump-slaps-50-tariff-on-canadian-steel-aluminum-threatens-auto-industry">Trump Slaps 50% Tariff On Canadian Steel &amp; Aluminum, Threatens Auto Industry</a>
This has presented a good opportunity to look into exchange-traded funds, <a href="https://www.benzinga.com/etfs">ETFs, that may gain or lose</a>:
<ul>
<li>VanEck Steel ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLX#NYSE">SLX</a>): The ETF gained 1.3% on Tuesday. Its U.S. exposure is at 53.78%, with Brazil and Australia following at 14.65% and 10.71%, respectively. SLX has the least exposure to Canada at less than 1%. The ETF carries an expense ratio of 56 basis points. Tariffs on materials imports from Canada bode well for domestic producers. SLX has exposure to United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) and Steel Dynamics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>).</li>
</ul>
<ul>
<li>iShares U.S. Basic Materials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYM#NYSE">IYM</a>): This fund appeals to investors seeking a conservative way to gain aluminum exposure. The ETF&#8217;s exposure is spread out to base metals stocks and other materials sectors like chemicals and forestry products. This makes it a less speculative investment. This reduces risks from an aluminum market downturn. The ETF holds stocks of aluminum leaders such as Alcoa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) and Reliance Steel &amp; Aluminum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RS#NYSE">RS</a>). Both stand to gain if the tariffs are implemented.</li>
</ul>
<ul>
<li>The Invesco Building &amp; Construction ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKB#NYSE">PKB</a>): One of the outcomes of the 50% (or even 25%) tariffs on steel and aluminum imported from Canada is that it will drive up materials prices in the U.S. Higher steel prices may weigh on the construction sector. This fund could face profitability issues as steel is a key raw material in the industry it is exposed to.</li>
</ul>
<ul>
<li>The Invesco Food &amp; Beverage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBJ#NYSE">PBJ</a>): This fund could see headwinds as higher aluminum costs may pressure the food and beverage bottling industry as well. Companies like Diageo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>), Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), and PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) likely to face increased costs.</li>
</ul>
<h2 class="wp-block-heading">U.S. Steel Industry Backs The Move</h2>
Despite the market jitters, U.S. steel manufacturers are largely in favor of the tariffs. In a <a href="https://www.steel.org/2025/03/five-steel-groups-pledge-support-for-steel-tariffs-applaud-actions/">letter </a>to the president, five steel industry executives, represented by American Iron and Steel Institute, expressed their strong support for the 25% tariffs. Moreover,&nbsp;Jesse Gary, the CEO of&nbsp;Century Aluminum&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENX#NASDAQ">CENX</a>) <a href="https://www.benzinga.com/markets/equities/25/03/44269301/trumps-25-tariffs-on-steel-and-aluminum-imports-take-effect-eu-retaliates-us-steel-nucor-century-aluminum-and-other-domestic-stocks-cheer">told the New York Times</a>, &#8220;The new tariffs will close those loopholes back up and enable us to begin investing again, and bring on more production here in the U.S.&#8221;
While steel producers in the U.S. are supportive, the aluminum industry has shown a mixed reaction. Alcoa CEO William Oplinger <a href="https://www.investopedia.com/alcoa-s-ceo-says-trump-tariffs-could-wipe-out-100-000-u-s-jobs-11686292">voiced </a>concerns that tariffs could hurt the U.S. aluminum sector due to the company's strong ties to Canadian operations.
The impact of tariffs will likely trickle down to consumers as well. Domestic steel prices have already surged from around $700 to nearly $1,000 per ton since Trump's initial announcement in February. A Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-03-11/trump-s-metal-tariffs-set-to-hit-favorites-like-baseball-bats-and-fishing-reels">report </a> said that higher costs could affect a range of products, from aluminum baseball bats to stainless steel cookware and fishing reels.
Investors should keep an eye on ETFs exposed to these sectors, as they may see significant movement in the coming weeks. Whether Trump follows through with the full 50% tariff or retreats from the threat, the ripple effects will be felt across multiple industries and investment tools.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/03/44285737/dailydelta-rolls-out-etfs-for-daily-nasdaq-100-index-movements">DailyDelta Rolls Out ETFs For Daily Nasdaq-100 Index Movements</a></li>
</ul>
Image: Midjourney

Sector ETFs

ETFs

CENX

iShares Trust Dow Jones US Basic Materials Sector Index Fund

PowerShares ETF Trust Dynamic Building &nstruction Portfolio

STLD

Steel & Aluminum Import Tariff Threat: 4 ETFs Gaining & Losing In The Market Shake-Up

Ratings for Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Voyager Therapeutics, revealing an average target of $18.93, a high estimate of $30.00, and a low estimate of $5.73. This current average represents a 21.13% decrease from the previous average price target of $24.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813448_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Voyager Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yanan Zhu</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Pete Stavropoulos</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$5.73</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Voyager Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Voyager Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Voyager Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Voyager Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VYGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Voyager Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Voyager Therapeutics</h2>
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
<h3>A Deep Dive into Voyager Therapeutics's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Voyager Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 433.79%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Voyager Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -36.72%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Voyager Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -2.72%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -2.1%, the company showcases effective utilization of assets.
Debt Management: Voyager Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VYGR

A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts

Bitcoin and Ethereum struggle to maintain gains, while XRP rallies on optimism over the SEC potentially closing its case against Ripple. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$82,997.45</td>
<td>-0.13%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$1,876.24</td>
<td>-3.7%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$124.56</td>
<td>-2.1%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.23</td>
<td>+2.5%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1689</td>
<td>+1.3%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001229</td>
<td>+0.8%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 5.2% and daily active addresses falling by 3.4%. Transactions greater than $100,000 are down from 11,844 to 10,766 in a single day. Exchanges netflows are down by 100.9%.</li>
<li>Coinglass data reports 97,058 traders were liquidated in the past 24 hours for $281.42 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44281794/binance-secures-2-billion-investment-from-abu-dhabi-mgx">Binance Secures $2 Billion Investment From Abu Dhabi MGX</a></li>
<li><a href="https://in.benzinga.com/25/03/44281569/rumble-buys-bitcoin-a-valuable-hedge-against-inflation">Rumble Buys Bitcoin: &#8216;A Valuable Hedge Against Inflation&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44272805/bitwise-launches-etf-tracking-firms-with-over-1000-bitcoin">Bitwise Launches ETF Tracking Firms With Over 1,000 Bitcoin</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44275216/bitcoin-to-defy-trump-tariffs-recession-fears-will-hit-200000-by-end-of-2025-standard-chartered">Bitcoin To Defy Trump Tariffs, Recession Fears, Will Hit $200,000 By End Of 2025: Standard Chartered</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44280122/after-vladimir-putin-said-nobody-can-ban-bitcoin-the-bank-of-russia-is-looking-to-allow-crypto-purchases">After Vladimir Putin Said &#8216;Nobody Can Ban Bitcoin&#8217;, The Bank Of Russia Is Looking To Allow Crypto Purchases</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Pi (CRYPTO: PI)</td>
<td>&nbsp;$1.70</td>
<td>+21.5%</td>
</tr>
<tr>
<td>Celestia (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>)</td>
<td>&nbsp;$3.58</td>
<td>+16%</td>
</tr>
<tr>
<td>Story (CRYPTO: IP)</td>
<td>&nbsp;$6.04</td>
<td>+9.7%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Intuitio <a href="https://x.com/intuitio_/status/1899854521553006880">argues</a> that Bitcoin has only had a taste of the bull market, while Ethereum never truly experienced one—it was merely in an echo bubble that has now deflated. 
With BTC retesting its previous all-time high, he believes the claim that "the bull run hasn't even begun" may hold weight.
Jelle <a href="https://x.com/CryptoJelleNL/status/1899839832035058101">sees</a> bears still in control, noting that Monday's highs were swept, followed by a lower low after a series of higher lows.
 He warns that when bearish setups play out cleanly, there's no reason to chase short-term upside—instead, patience is key.
Moustache aka El Crypto Prof points out that the last time the S&amp;P 500's daily RSI was this low, Bitcoin rallied over 300% afterward. With both BTC and the S&amp;P 500 touching a key trendline, he believes this could be a bullish signal.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> The last time the RSI in the S&amp;P 500 (D) was this low, <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> rose more than 300% thereafter. -Both assets are also touching a very important trend line Be more bullish guys. <a href="https://t.co/SLuHrzk7ZF">pic.twitter.com/SLuHrzk7ZF</a>
&mdash; 
</blockquote></div></figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$TIA

$XRP

Bitcoin, Ethereum Slip, XRP, Dogecoin Hold Gains On Slow Wednesday

Analysts' ratings for United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.22, along with a high estimate of $140.00 and a low estimate of $110.00. This upward trend is evident, with the current average reflecting a 8.99% increase from the previous average price target of $118.56.
<img src="https://www.benzinga.com/files/images/story/2025/1741813417_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive United Airlines Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$110.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ravi Shanker</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jamie Baker</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$120.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Savanthi Syth</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to United Airlines Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Airlines Holdings compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Airlines Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into United Airlines Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/UAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on United Airlines Holdings analyst ratings.</a>
<h2>Unveiling the Story Behind United Airlines Holdings</h2>
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
<h3>United Airlines Holdings: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining United Airlines Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.85% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: United Airlines Holdings's net margin excels beyond industry benchmarks, reaching 6.7%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): United Airlines Holdings's ROE excels beyond industry benchmarks, reaching 8.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): United Airlines Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.34%, the company showcases efficient use of assets and strong financial health.
Debt Management: United Airlines Holdings's debt-to-equity ratio is below the industry average at 2.65, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: United Airlines Holdings In The Eyes Of 9 Experts

Buybacks

Metropolitan Bank Plans $50M Stock Repurchase Program

During the last three months, 11 analysts shared their evaluations of Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.62, a high estimate of $8.00, and a low estimate of $5.00. Highlighting a 13.8% decrease, the current average has fallen from the previous average price target of $7.68. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813407_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Bumble by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Shweta Khajuria</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Matt Farrell</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.80</td>
<td>$8.00</td>
</tr>
<tr>
<td>Nathan Feather</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$7.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bumble. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bumble compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bumble's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Bumble's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BMBL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bumble analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Bumble</h2>
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
<h3>Bumble: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Bumble's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -4.38%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Bumble's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.59%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Bumble's ROE stands out, surpassing industry averages. With an impressive ROE of 1.12%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bumble's ROA excels beyond industry benchmarks, reaching 0.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Bumble's debt-to-equity ratio is below the industry average. With a ratio of 0.76, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMBL

Beyond The Numbers: 11 Analysts Discuss Bumble Stock

Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) announced first-quarter financial results Wednesday after the bell. Here&#8217;s a rundown <a href="http://benzinga.com/quote/adbe">of the report</a>.
Q1 Earnings: Adobe reported first-quarter revenue of $5.71 billion, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $5.66 billion. The company reported first-quarter adjusted earnings of $5.08 per share, beating analyst estimates of $4.97 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year. Broken down by segment, digital media revenue was up 11% year-over-year and digital experience revenue climbed 10% year-over-year.
Remaining performance obligations came in at $19.69 billion and cash flows from operations totaled $2.48 billion in the first quarter. 
Adobe noted it repurchased approximately seven million shares during the period. The company ended the quarter with $6.76 billion in cash and cash equivalents.
&#8220;Adobe&#8217;s success over the next decade will be driven by customer-focused innovation and new offerings for creators, marketing professionals, business professionals and consumers,&#8221; said&nbsp;Shantanu Narayen, chair and CEO of Adobe.
&#8220;Adobe is well-positioned to capitalize on the acceleration of the creative economy driven by AI and we are reaffirming our FY2025 financial targets.&#8221;
See Also: <a href="https://www.benzinga.com/25/03/44284016/tesla-to-120-here-are-10-top-analyst-forecasts-for-wednesday">Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday</a>
Outlook: Adobe expects second-quarter revenue of $5.77 billion to $5.82 billion versus estimates of $5.8 billion. The company anticipates second-quarter adjusted earnings of $4.95 to $5 per share versus estimates of $5 per share.
Adobe reaffirmed expectations for full-year 2025 revenue between $23.3 billion and $23.55 billion versus estimates of $23.5 billion. Adobe sees full-year adjusted earnings in the range of $20.20 to $20.50 per share versus estimates of $20.40 per share.
Adobe noted it will host an Investor Meeting on March 18 at the Adobe Summit to provide updates on its strategy and roadmap.
Adobe executives will further discuss the quarter on a call with investors and analysts from 5 p.m. to 6 p.m. ET.
ADBE Price Action: <a href="https://www.benzinga.com/quote/ADBE" target="_blank" rel="noreferrer noopener">Adobe shares</a> were down 3.33% after-hours, trading at $438.60 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

ADBE

Adobe Q1 Earnings: Revenue Beat, EPS Beat, Reaffirmed FY Guidance And More

4 analysts have shared their evaluations of RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $4.75, a high estimate of $5.00, and a low estimate of $4.00. This current average represents a 23.01% decrease from the previous average price target of $6.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813394_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive RumbleON. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$5.50</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Michael Baker</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$5.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RumbleON. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of RumbleON compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for RumbleON's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of RumbleON's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RMBL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on RumbleON analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering RumbleON: A Closer Look</h2>
RumbleON Inc is a USA-based online retailer that allows both consumers and dealers to Buy-Sell-Trade-Finance pre-owned motorcycles in an efficient, fast, transparent, and engaging experience. Its segments include power sports, automotive, and vehicle logistics. Powersports and automotive segments consist of the distribution of pre-owned vehicles. The Powersports segment that derives the majority of revenue consists of the distribution principally of motorcycles and other powersports vehicles, while the automotive segment distributes cars and trucks. The vehicle Logistics and transportation service segment offers nationwide automotive transportation services between dealerships and auctions.
<h3>Financial Insights: RumbleON</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining RumbleON's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -12.75% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.8%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): RumbleON's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -12.68%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): RumbleON's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.3%, the company may face hurdles in achieving optimal financial performance.
Debt Management: RumbleON's debt-to-equity ratio is below the industry average at 7.5, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RMBL

RumbleON Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $146.11, a high estimate of $160.00, and a low estimate of $120.00. This current average has increased by 10.79% from the previous average price target of $131.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813385_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Silicon Laboratories's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Philip Gibbs</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Announces</td>
<td>Neutral</td>
<td>$130.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Silicon Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Silicon Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Silicon Laboratories's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SLAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Silicon Laboratories analyst ratings.</a>
<h2>Get to Know Silicon Laboratories Better</h2>
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
<h3>Key Indicators: Silicon Laboratories's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Silicon Laboratories's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 91.43%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -14.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -2.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -1.93%, the company showcases effective utilization of assets.
Debt Management: Silicon Laboratories's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SLAB

Analyst Expectations For Silicon Laboratories's Future

Analysts' ratings for Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.0, a high estimate of $8.00, and a low estimate of $8.00. The average price target has stayed the same, reflecting a consistent view from analysts. 
<img src="https://www.benzinga.com/files/images/story/2025/1741813376_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Brookdale Senior Living by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Brookdale Senior Living. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Brookdale Senior Living compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Brookdale Senior Living's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Brookdale Senior Living's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BKD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Brookdale Senior Living analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Brookdale Senior Living</h2>
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
<h3>Brookdale Senior Living's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Brookdale Senior Living showcased positive performance, achieving a revenue growth rate of 3.51% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Brookdale Senior Living's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -33.21%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.37%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 26.6, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Brookdale Senior Living Stock

Press Releases

Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development

Guardant Health's Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Guardant Health Announces Debt Exchange Transactions

Guardant Health to Participate in Upcoming Investor Conferences

Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

Guardant Health Receives ADLT Status From CMS for Shield Blood Test

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Guardant Health

ニュース

パートナーシップ

ベンジンガ・グローバル